Market Overview:
The global allergy treatment market size reached US$ 22.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 22.3 Billion |
Market Forecast in 2032
|
US$ 35.5 Billion |
Market Growth Rate 2024-2032 |
5.2% |
Allergy treatment is a preventive medical cure for abnormal reactions to allergens, such as pollens, molds, animal dander, latex, insects, food, and medications. They trigger the release of histamine by the immune system that causes inflammation, rashes, itchiness, sneezing, runny nose, and red eyes. They can also cause various allergic conditions, including hay fever, asthma, rhinitis, and skin, food, and eye allergies. Allergy treatment includes anti-allergic drugs and immunotherapy that can be administered through oral, inhalers, and intranasal dosage forms. These treatment methods help reduce sensitivity and inflammation, decrease symptoms, and improve the quality of the patient’s life.
Allergy Treatment Market Trends:
The increasing prevalence of various allergies across the globe is one of the primary factors driving the market growth. In line with this, favorable initiatives by governments and non-governmental organizations (NGOs) to sensitize the masses about the adversities of allergies and their appropriate treatment options are favoring the market growth. Furthermore, increasing demand for over-the-counter (OTC) drugs, coupled with a growing inclination toward self-medication among consumers, is acting as another growth-inducing factor. Additionally, the integration of artificial intelligence (AI), natural language processing (NLP), and machine learning (ML) for diagnosing allergic diseases, predicting patient outcomes for targeted interventions, analyzing immunological data, and improving care delivery is providing an impetus to market growth. Apart from this, the increasing demand for subcutaneous allergen-specific immunotherapy (SCIT) due to its effectiveness, safety, and ability to alter the immune system and provide systemic relief is creating a positive outlook for the market. Other factors, including significant healthcare expenditures, increasing geriatric population, extensive research and development (R&D) activities towards novel treatments, and rising incidences of asthma, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global allergy treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, treatment, dosage form and distribution channel.
Breakup by Type:
- Eye Allergy
- Skin Allergy
- Food Allergy
- Asthma
- Rhinitis
- Others
Breakup by Treatment:
- Anti-Allergy Drugs
- Immunotherapy
Breakup by Dosage Form:
- Oral
- Inhalers
- Intranasal
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Retailers
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., ALK-Abelló A/S, Allergopharma (Dermapharm AG), Allergy Therapeutics, Almirall S.A, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, HAL Allergy Group (Droege International Group), Leti Pharma, Nicox S.A., Sanofi S.A. and Stallergenes Greer.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Type, Treatment, Dosage Form, Distribution Channel, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
AbbVie Inc., ALK-Abelló A/S, Allergopharma (Dermapharm AG), Allergy Therapeutics, Almirall S.A, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, HAL Allergy Group (Droege International Group), Leti Pharma, Nicox S.A., Sanofi S.A. and Stallergenes Greer |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |